Abstract
Impaired glucose uptake in the brain is one of the earliest presymptomatic manifestations of Alzheimer’s disease (AD). The absence of symptoms for extended periods of time suggests that compensatory metabolic mechanisms can provide resilience. Here, we introduce the concept of a systemic ‘bioenergetic capacity’ as the innate ability to maintain energy homeostasis under pathological conditions, potentially serving as such a compensatory mechanism. We argue that fasting blood acylcarnitine profiles provide an approximate peripheral measure for this capacity that mirrors bioenergetic dysregulation in the brain. Using unsupervised subgroup identification, we show that fasting serum acylcarnitine profiles of participants from the AD Neuroimaging Initiative yields bioenergetically distinct subgroups with significant differences in AD biomarker profiles and cognitive function. To assess the potential clinical relevance of this finding, we examined factors that may offer diagnostic and therapeutic opportunities. First, we identified a genotype affecting the bioenergetic capacity which was linked to succinylcarnitine metabolism and significantly modulated the rate of future cognitive decline. Second, a potentially modifiable influence of beta-oxidation efficiency seemed to decelerate bioenergetic aging and disease progression. Our findings, which are supported by data from more than 9,000 individuals, suggest that interventions tailored to enhance energetic health and to slow bioenergetic aging could mitigate the risk of symptomatic AD, especially in individuals with specific mitochondrial genotypes.
Competing Interest Statement
A.J.S is a member of the Scientific Advisory Board of Bayer Oncology and of the Dementia Advisory Board of Siemens Medical Solutions USA, Inc.; A.J.S received in kind support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (PET tracer precursor); A.J.S. received Editorial Office Support as Editor-in-Chief from SPringer-Nature Publishing (Brain Imaging and Behavior). P.M.D. has received research grants (through Duke University) from Lilly, Avanir, Bausch, Alzheimer's Drug Discovery Foundation; P.M.D has received advisory fees from Verily, Otsuka, Genomind, Cogniciti, Clearview, VitaKey, Neuronix, Neuroglee, and Transposon Therapeutics; P.M.D owns shares or options in UMethod, Evidation Healthy, Transposon, Marvel Biome, and Advera Health; P.M.D serves on the board of Apollo and is a co-inventor (through Duke University) on patents relating to dementia biomarkers, metabolomics, and therapies. R.K.D holds equity in Metabolon Inc. M.A., R.K.D., and G.K. are co-inventors (through Duke University/Helmholtz Zentrum Muenchen) on patents on applications of metabolomics in disease of the central nervous system; M.A., R.K.D., G.K., and J.K. hold equity in Chymia LLC and IP in PsyProtix/atai Life Sciences N.V. that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression. J.K is confounder of iollo and advisor to Celeste Health and Strand Health.
Funding Statement
This work was supported by the National Institutes of Health/the National Institute of Aging through grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744 and R01AG069901. In addition, the following funding sources are acknowledged: ADNI: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data collection and sharing for this project was further funded by the Alzheimer's Disease Metabolomics Consortium (National Institute on Aging R01AG046171, RF1AG051550 and 3U01AG024904-09S4). ROS/MAP: Study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at www.radc.rush.edu. MayoLOAD: Study data were provided by the Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. KORA: The KORA study was initiated and financed by the Helmholtz Zentrum Muenchen - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. AGES-RS: The AGES-RS study has been funded by NIH contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association) contract HHSN271201200022C, and the Althingi (the Icelandic Parliament). Funding sources had no role in study design, the collection, analysis and interpretation of data, the writing of the report, or in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Duke University gave ethical approval for using ROS/MAP data (Pro00072976). IRB of Duke University waived ethical approval (determined exempt) for using ADNI-1/GO/2 data (Pro00053208) and AGES-RS data (Pro00093250). Data use agreements of KORA and MayoLOAD studies did not require separate IRB approval. MayoLOAD was approved by the appropriate IRB and appropriate informed consent was obtained from all participants. KORA, including the protocols for subject recruitment and assessment and the informed consent for participants, was reviewed and approved by the local ethical committee (Bayerische Landesaerztekammer).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
